|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
389,580,000 |
Market
Cap: |
49.50(B) |
Last
Volume: |
1,689,979 |
Avg
Vol: |
1,912,163 |
52
Week Range: |
$75.49 - $140.45 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 487 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile DexCom is a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems. Co.'s product candidates include Dexcom G7®, which is designed with the goal of carrying forward many of the same features as Co.'s G6 CGM system and adding several new or improved features. Co.'s products include: DexCom G6® integrated Continuous Glucose Monitoring System (G6), which is a type of CGM system to be used as part of an integrated system with other medical devices and electronic interfaces; and DexCom Share®, which transmit glucose information to the cloud and then to apps on the mobile devices of up to five designated recipients.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
214,480 |
278,554 |
302,923 |
570,485 |
Total Sell Value |
$28,881,982 |
$36,708,660 |
$39,498,005 |
$69,560,865 |
Total People Sold |
7 |
10 |
14 |
15 |
Total Sell Transactions |
14 |
27 |
46 |
79 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Flynn Paul R |
EVP Global Revenue |
|
2023-04-17 |
4 |
AS |
$120.00 |
$333,720 |
D/D |
(2,781) |
52,112 |
|
-15% |
|
Stern Sadie |
EVP Chief Human Resources Offi |
|
2023-04-10 |
4 |
AS |
$112.35 |
$44,154 |
D/D |
(393) |
83,252 |
|
-4% |
|
Brown Micheal Jon |
EVP Chief Legal Officer |
|
2023-04-03 |
4 |
AS |
$114.07 |
$413,490 |
D/D |
(3,612) |
61,870 |
|
-3% |
|
Sayer Kevin R |
President CEO and Chairman of |
|
2023-04-03 |
4 |
AS |
$113.83 |
$2,382,069 |
D/D |
(20,812) |
327,457 |
|
-3% |
|
Pacelli Steven Robert |
EVP Managing Director Dexcom V |
|
2023-03-23 |
4 |
AS |
$116.40 |
$633,449 |
D/D |
(5,442) |
138,129 |
|
8% |
|
Dolan Matthew Vincent |
SVP Corporate Strategy-Develop |
|
2023-03-16 |
4 |
AS |
$115.00 |
$264,845 |
D/D |
(2,303) |
33,569 |
|
14% |
|
Flynn Paul R |
EVP Global Revenue |
|
2023-03-13 |
4 |
AS |
$106.27 |
$295,643 |
D/D |
(2,782) |
54,893 |
|
18% |
|
Regan Barry J. |
EVP Operations |
|
2023-03-13 |
4 |
AS |
$106.27 |
$213,603 |
D/D |
(2,010) |
70,472 |
|
18% |
|
Dolan Matthew Vincent |
SVP Corporate Strategy-Develop |
|
2023-03-13 |
4 |
AS |
$106.27 |
$661,956 |
D/D |
(6,229) |
35,872 |
|
18% |
|
Flynn Paul R |
EVP Global Revenue |
|
2023-03-10 |
4 |
D |
$111.40 |
$1,876,516 |
D/D |
(16,845) |
57,675 |
|
- |
|
Brown Micheal Jon |
EVP Chief Legal Officer |
|
2023-03-10 |
4 |
D |
$111.40 |
$536,052 |
D/D |
(4,812) |
65,482 |
|
- |
|
Abbey Donald |
EVP Global Business Services I |
|
2023-03-10 |
4 |
D |
$111.40 |
$1,299,915 |
D/D |
(11,669) |
208,023 |
|
- |
|
Stern Sadie |
EVP Chief Human Resources Offi |
|
2023-03-10 |
4 |
D |
$111.40 |
$681,205 |
D/D |
(6,115) |
84,038 |
|
- |
|
Regan Barry J. |
EVP Operations |
|
2023-03-10 |
4 |
D |
$111.40 |
$632,746 |
D/D |
(5,680) |
72,482 |
|
- |
|
Sylvain Jereme M |
EVP Chief Financial Officer |
|
2023-03-10 |
4 |
D |
$111.40 |
$1,071,436 |
D/D |
(9,618) |
77,111 |
|
- |
|
Selvaraj Shelly Ramasamy |
SVP Chief Information Officer |
|
2023-03-10 |
4 |
D |
$111.40 |
$720,974 |
D/D |
(6,472) |
54,512 |
|
- |
|
Pacelli Steven Robert |
EVP Managing Director Dexcom V |
|
2023-03-10 |
4 |
D |
$111.40 |
$1,299,915 |
D/D |
(11,669) |
143,571 |
|
- |
|
Leach Jacob Steven |
EVP Chief Technology Officer |
|
2023-03-10 |
4 |
D |
$111.40 |
$1,794,526 |
D/D |
(16,109) |
290,377 |
|
- |
|
Balo Andrew K |
EVP Regulatory Strategy Clinic |
|
2023-03-10 |
4 |
D |
$111.40 |
$1,300,026 |
D/D |
(11,670) |
50,908 |
|
- |
|
Dolan Matthew Vincent |
SVP Corporate Strategy-Develop |
|
2023-03-10 |
4 |
D |
$111.40 |
$691,119 |
D/D |
(6,204) |
42,101 |
|
- |
|
Sayer Kevin R |
President CEO and Chairman of |
|
2023-03-10 |
4 |
D |
$111.40 |
$4,176,349 |
D/D |
(37,490) |
348,269 |
|
- |
|
Flynn Paul R |
EVP Global Revenue |
|
2023-03-08 |
4 |
A |
$0.00 |
$19 |
D/D |
18,776 |
74,520 |
|
- |
|
Sylvain Jereme M |
EVP Chief Financial Officer |
|
2023-03-08 |
4 |
A |
$0.00 |
$22 |
D/D |
21,769 |
86,729 |
|
- |
|
Abbey Donald |
EVP Global Business Services I |
|
2023-03-08 |
4 |
A |
$0.00 |
$19 |
D/D |
18,776 |
219,692 |
|
- |
|
Naganathan Girish |
EVP Chief Technology Officer |
|
2023-03-08 |
4 |
A |
$0.00 |
$19 |
D/D |
18,776 |
50,225 |
|
- |
|
2278 Records found
|
|
Page 5 of 92 |
|
|